What changed: Recurrent and metastatic nasopharyngeal carcinoma
Every dated change on the records linked to Recurrent and metastatic nasopharyngeal carcinoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
September 2026 · 1
2025 · 1
2023 · 2
- 2023ApprovalToripalimabToripalimab approved in US
Recurrent/metastatic nasopharyngeal carcinoma, first line with chemotherapy and later lines
- 2023MilestoneToripalimabToripalimab approved in the United States for nasopharyngeal carcinoma; hyperfractionated re-irradiation trial published
A milestone in how this cancer is treated.
2021 · 8
- 2021GuidelineRecurrent and metastatic nasopharyngeal carcinomaGuideline CSCO/ASCO guideline on nasopharyngeal carcinoma 2021; NCCN Head and Neck Cancers: After platinum and PD-1 therapy
Gemcitabine, taxane or capecitabine-based chemotherapy; nivolumab or pembrolizumab if no prior PD-1 antibody; trials of antibody-drug conjugates (MRG003, BL-B01D1, YL201) and EBV-specific T cells.
- 2021GuidelineRecurrent and metastatic nasopharyngeal carcinomaGuideline CSCO/ASCO guideline on nasopharyngeal carcinoma 2021; NCCN Head and Neck Cancers: Metastatic disease, first line
Gemcitabine and cisplatin with a PD-1 antibody (toripalimab, JUPITER-02; camrelizumab, CAPTAIN-1st; tislelizumab; penpulimab), then PD-1 maintenance; locoregional radiotherapy to the primary in patients with a good response.
- 2021GuidelineRecurrent and metastatic nasopharyngeal carcinomaGuideline CSCO/ASCO guideline on nasopharyngeal carcinoma 2021; NCCN Head and Neck Cancers: Oligometastatic disease
Stereotactic radiotherapy or resection of limited metastases with systemic therapy.
- 2021GuidelineRecurrent and metastatic nasopharyngeal carcinomaGuideline CSCO/ASCO guideline on nasopharyngeal carcinoma 2021; NCCN Head and Neck Cancers: Resectable local recurrence
Endoscopic nasopharyngectomy (better survival and fewer complications than re-irradiation in a randomised trial); neck dissection for nodal recurrence.
- 2021GuidelineRecurrent and metastatic nasopharyngeal carcinomaGuideline CSCO/ASCO guideline on nasopharyngeal carcinoma 2021; NCCN Head and Neck Cancers: Unresectable local recurrence
Hyperfractionated intensity-modulated re-irradiation or proton therapy with careful dose constraints; systemic therapy where re-irradiation is unsafe.
- 2021Trial resultCAPTAIN-1stCAPTAIN-1st reported
Median progression-free survival 9.
- 2021Trial resultJUPITER-02JUPITER-02 reported
PFS HR 0.
- 2021MilestoneJUPITER-02JUPITER-02 and CAPTAIN-1st: PD-1 antibodies with gemcitabine-cisplatin lengthen progression-free survival; endoscopic nasopharyngectomy beats re-irradiation
A milestone in how this cancer is treated.